3) A randomized trial is conducted to evaluate the efficacy of a new cholesterol lowering medication. The primary outcome is incident coronary artery disease. Participants are free of coronary artery disease at the start of the study and randomized to receive either the new medication or a placebo. Participants are followed for a maximum of 10 years for the development of coronary artery disease.

The following data are:

Number participants number with coronary artery disease

Cholesterol medication 400 28

Placebo 400 42

Compute the Relative Risk of coronary artery disease in patients receiving the new medication as compared to placebo.Compute the Odd ratio of coronary artery disease in patients receiving the new medications as compared to placebo

Odds Ratio =